Affordable Access

Publisher Website

Meeting Synopsis: Advances in Skeletal Muscle Biology in Health and Disease (Gainesville, Florida, February 22nd to 24th 2012) – Day 2: “Muscle Diseases and Regeneration” and “Clinical/Translational Research”

Authors
Journal
Frontiers in Physiology
1664-042X
Publisher
Frontiers Media SA
Publication Date
Volume
3
Identifiers
DOI: 10.3389/fphys.2012.00201
Keywords
  • Physiology
  • Opinion Article
Disciplines
  • Biology
  • Medicine

Abstract

Meeting synopsis: advances in skeletal muscle biology in health and disease (Gainesville, Florida, February 22nd to 24th 2012) – day 2: “muscle diseases and regeneration” and “clinical/translational research” OpiniOn Article published: 11 June 2012 doi: 10.3389/fphys.2012.00201 Meeting synopsis: advances in skeletal muscle biology in health and disease (Gainesville, Florida, February 22nd to 24th 2012) – day 2: “muscle diseases and regeneration” and “clinical/translational research” Andrew R. Judge1,2*, Scott K. Powers 2, Leonardo F. Ferreira 2 and Marcas M. Bamman3 1 Department of Physical Therapy, University of Florida, Gainesville, FL, USA 2 Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL, USA 3 UAB Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, USA *Correspondence: [email protected] Dr. Girgenrath discussed her data on MDC1A, which is a severe form of con- genital muscular dystrophy character- ized by hypotonia, muscle weakness, and premature death. MDC1A results from deficiency in the laminin alpha 2 chain of laminin-211, an extracellular matrix pro- tein mainly found in skeletal muscle and Schwann cells. Defects in laminin-211 cause major disruption of structural stability and signal transduction that leads to apoptosis, failed regeneration, and chronic inflamma- tion. An emerging idea in the study of mul- tiple diseases is that different pathological processes are intimately connected and can even amplify one another; this theory may apply to MDC1A. Dr. Girgenrath presented data showing that while targeting regenera- tion or apoptotic processes alone result in measurable improvement in the pathol- ogy of MDC1A/DyW mice, a combinato- rial therapeutic approach that targets both results in marked improvement in pathology with larger, more uniform myofiber size as well as improved regeneration and reduced fibrosis. Dr. Girgenrath’s results suggest that dual therapy has promisin

There are no comments yet on this publication. Be the first to share your thoughts.